DarioHealth Corp [DRIO] stock is trading at $0.79, up 0.03%. An important factor to consider is whether the stock is rising or falling in short-term value. The DRIO shares have gain 12.70% over the last week, with a monthly amount drifted -0.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
DarioHealth Corp [NASDAQ: DRIO] stock has seen the most recent analyst activity on May 13, 2022, when Alliance Global Partners upgraded its rating to a Buy but kept the price target unchanged to $8.75 for it. Previously, Cowen started tracking the stock with Outperform rating on April 22, 2021, and set its price target to $31. On March 23, 2021, Stifel initiated with a Buy rating and assigned a price target of $30 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $35 on February 25, 2021. Alliance Global Partners downgraded its rating to a Neutral and raised its price target to $22.25 on February 01, 2021. Aegis Capital started tracking with a Buy rating for this stock on August 17, 2020, and assigned it a price target of $25. In a note dated August 29, 2017, Aegis Capital initiated an Buy rating and provided a target price of $3.50 on this stock.
DarioHealth Corp [DRIO] stock has fluctuated between $0.63 and $2.60 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. DarioHealth Corp [NASDAQ: DRIO] shares were valued at $0.79 at the most recent close of the market. An investor can expect a potential return of 1260.76% based on the average DRIO price forecast.
Analyzing the DRIO fundamentals
DarioHealth Corp [NASDAQ:DRIO] reported sales of 23.05M for the trailing twelve months, which represents a growth of 111.00%. Gross Profit Margin for this corporation currently stands at 0.4% with Operating Profit Margin at -2.58%, Pretax Profit Margin comes in at -0.97%, and Net Profit Margin reading is -1.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.53 and Total Capital is -0.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7484 points at the first support level, and at 0.7107 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8364, and for the 2nd resistance point, it is at 0.8867.
Ratios To Look Out For
For context, DarioHealth Corp’s Current Ratio is 1.57. On the other hand, the Quick Ratio is 1.32, and the Cash Ratio is 0.82. Considering the valuation of this stock, the price to sales ratio is 1.30, the price to book ratio is 0.42.
Transactions by insiders
Recent insider trading involved Nelson Steven Charles, Chief Commercial Officer, that happened on Nov 12 ’24 when 5000.0 shares were purchased. Chief Commercial Officer, Nelson Steven Charles completed a deal on Sep 10 ’24 to buy 5000.0 shares. Meanwhile, Chief Commercial Officer Nelson Steven Charles bought 5000.0 shares on Sep 11 ’24.
